- Home
- BUJA vs IMMX Comparison
BUJA vs IMMX Comparison
Compare BUJA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- IMMX
- Stock Information
- Founded
- BUJA 2022
- IMMX 2014
- Country
- BUJA Malaysia
- IMMX United States
- Employees
- BUJA N/A
- IMMX N/A
- Industry
- BUJA Blank Checks
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BUJA Finance
- IMMX Health Care
- Exchange
- BUJA Nasdaq
- IMMX Nasdaq
- Market Cap
- BUJA 55.2M
- IMMX 46.8M
- IPO Year
- BUJA 2023
- IMMX 2021
- Fundamental
- Price
- BUJA N/A
- IMMX $2.28
- Analyst Decision
- BUJA
- IMMX Strong Buy
- Analyst Count
- BUJA 0
- IMMX 1
- Target Price
- BUJA N/A
- IMMX $7.00
- AVG Volume (30 Days)
- BUJA 14.2K
- IMMX 274.3K
- Earning Date
- BUJA 01-01-0001
- IMMX 11-12-2024
- Dividend Yield
- BUJA N/A
- IMMX N/A
- EPS Growth
- BUJA N/A
- IMMX N/A
- EPS
- BUJA 0.25
- IMMX N/A
- Revenue
- BUJA N/A
- IMMX N/A
- Revenue This Year
- BUJA N/A
- IMMX N/A
- Revenue Next Year
- BUJA N/A
- IMMX $200.00
- P/E Ratio
- BUJA $44.25
- IMMX N/A
- Revenue Growth
- BUJA N/A
- IMMX N/A
- 52 Week Low
- BUJA $10.37
- IMMX $1.26
- 52 Week High
- BUJA $12.18
- IMMX $7.50
- Technical
- Relative Strength Index (RSI)
- BUJA 93.47
- IMMX 56.24
- Support Level
- BUJA $10.95
- IMMX $1.88
- Resistance Level
- BUJA $11.18
- IMMX $2.33
- Average True Range (ATR)
- BUJA 0.00
- IMMX 0.29
- MACD
- BUJA 0.00
- IMMX -0.02
- Stochastic Oscillator
- BUJA 100.00
- IMMX 44.58
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.